The main department of described VC is located in the New Haven. The venture was found in North America in United States.
The current fund was established by Rob Bettigole. The overall number of key employees were 3.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Elm Street Ventures, startups are often financed by Connecticut Innovations, OUP (Osage University Partners), MPM Capital. The meaningful sponsors for the fund in investment in the same round are Connecticut Innovations, OUP (Osage University Partners), Xeraya Capital. In the next rounds fund is usually obtained by RA Capital Management, OrbiMed, New Leaf Venture Partners.
Deals in the range of 5 - 10 millions dollars are the general things for fund. Comparing to the other companies, this Elm Street Ventures performs on 4 percentage points more the average number of lead investments. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2009. Considering the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The higher amount of exits for fund were in 2019.
Among the most popular portfolio startups of the fund, we may highlight Iconic Therapeutics, Retail Optimization, SeeClickFix. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Consumer.
Related Funds
Funds with similar focus
Fund Name | Location |
China Investment Corporation | Beijing, Beijing, China |
City Developments | Central, Central Region, Singapore |
Elite Joint | China, Guangdong, Tianjin |
Fuqua Investments | - |
Mashreq Bank | Dubai, United Arab Emirates |
Reliance Entertainment | - |
TaskRabbit | California, San Francisco, United States |
VKRM Ventures | California, Los Altos, United States |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Halda Therapeutics | $126M | 12 Aug 2024 | Branford, Connecticut, United States | ||
CellFE | $22M | 27 Sep 2023 | California, United States | ||
P2 Science | 23 Feb 2023 | Connecticut, United States | |||
Allyx Therapeutics | $7M | 01 Jun 2021 | New Haven, New York, United States | ||
Cybrexa Therapeutics | $25M | 10 Mar 2021 | New Haven, Connecticut, United States | ||
Artizan Biosciences | $18M | 01 Mar 2021 | New York, New York, United States | ||
Halda Therapeutics | $25M | 13 Nov 2020 | Branford, Connecticut, United States | ||
P2 Science | $12M | 29 Jan 2020 | Connecticut, United States | ||
CellFE | $4M | 16 Jan 2020 | California, United States |
– Cybrexa Therapeutics from New Haven develops a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform.
– The company completed its $25m Series B financing.
– Backers included HighCape Capital and new investor Elm Street Ventures.
– The new investment will be aimed at planned advancement of its lead candidate CBX-12 (alphalex™-exatecan) into the clinic.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Halda Therapeutics | $126M | 12 Aug 2024 | Branford, Connecticut, United States | ||
CellFE | $22M | 27 Sep 2023 | California, United States | ||
P2 Science | 23 Feb 2023 | Connecticut, United States | |||
Allyx Therapeutics | $7M | 01 Jun 2021 | New Haven, New York, United States | ||
Cybrexa Therapeutics | $25M | 10 Mar 2021 | New Haven, Connecticut, United States | ||
Artizan Biosciences | $18M | 01 Mar 2021 | New York, New York, United States | ||
Halda Therapeutics | $25M | 13 Nov 2020 | Branford, Connecticut, United States | ||
P2 Science | $12M | 29 Jan 2020 | Connecticut, United States | ||
CellFE | $4M | 16 Jan 2020 | California, United States |